Lilly Becomes Top Pharma by Revenue as Mounjaro and Zepbound Drive $36.5B Growth

Eli Lilly has become the top pharmaceutical company by revenue, driven primarily by its diabetes drug Mounjaro and weight-loss medication Zepbound. According to Drug Discovery & Development, Mounjaro revenue grew 99% while Zepbound surged 175%, with the two drugs combining for $36.5 billion in fiscal year 2025.

The growth trajectory exceeded previous projections, with Lilly overtaking Merck approximately one year earlier than analysts had predicted in late 2026. The company's 2026 revenue guidance of $80-83 billion already surpasses base-case models that projected $77.2 billion for that year.

Lilly's revenue transformation has been dramatic over the past five years. The company posted $24.5 billion in revenue in 2020, meaning it has more than tripled its revenue in just five years through the success of its GLP-1 receptor agonist portfolio.

The milestone reflects the massive market opportunity in diabetes and obesity treatments, with Lilly capitalizing on strong demand for its incretin-based therapies. The company's ascension to the top revenue position among pharmaceutical companies marks a significant shift in industry rankings, displacing traditional leaders through focused execution in high-growth therapeutic areas.

◆ AI Agent Context

This brief focuses on the most significant story from the sources - Lilly's achievement as the top pharma company by revenue. Two other unrelated stories about psychedelics funding and egg-based biologics were excluded to maintain focus. Revenue figures and growth percentages are reported exactly as stated in the source. Confidence Notes: The brief relies on a single source (Drug Discovery & Development) for all the specific financial claims, including the $36.5 billion figure, the 99% and 175% growth rates, and the 2026 guidance—none of which can be independently verified against the other provided sources. The brief also presents 2020 revenue ($24.5B) and projects 2026 guidance ($80-83B) as established fact without acknowledging these are forward-looking statements subject to revision. Missing are perspectives from Wall Street analysts, Novo Nordisk or other competitor executives who might dispute Lilly's durability as market leader, and no discussion of patent cliffs, regulatory risks, or manufacturing scale-up challenges that could impact the projected trajectory.

// Counter-Argument

While Lilly's GLP-1 growth is impressive, the brief overlooks that obesity and diabetes markets are becoming increasingly commoditized with multiple competitors. Novo Nordisk's Ozempic and Wegovy already have established market presence and physician relationships, and the rapid emergence of cheaper biosimilars—particularly from companies like Samsung Bioepis—could compress Lilly's pricing power and margin expansion. Furthermore, the brief doesn't address that Mounjaro's 99% growth and Zepbound's 175% growth are partly inflated by base effects in early market penetration years; sustaining such growth rates as markets mature is historically difficult for pharma, and penetration may plateau faster than current guidance assumes given access, insurance, and manufacturing constraints.

Intelligence briefs are AI-generated from multiple sources for informational purposes only. Confidence scores, bias analysis, and consensus assessments reflect automated processing and may not capture all context. Verify critical information independently.

Lilly Becomes Top Pharma by Revenue as Mounjaro and Zepbound Drive $36.5B Growth

// Source Contradictions

// Source Consensus

// Key Events

// Entities

// Key Data

// Source Verification

// Takes & Comments